Pulmonary Cell News Volume 9.21 | Jun 4 2020

TOP STORY

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate

Scientists used mouse and human models with a time-series single-cell transcriptome analysis to reveal that MYC drove dynamic evolution of small cell lung cancer subtypes. [Cancer Cell] Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

Monocyte-Derived Multipotent Cell Delivered Programmed Therapeutics to Reverse Idiopathic Pulmonary Fibrosis

Released astaxanthin enhanced synergetic effect of trametinib for inhibiting myofibroblast activation, and monocyte-derived multipotent cells also repaired injured type II alveolar epithelial cells to promote damaged lung regeneration. [Sci Adv] Full Article

Lung Fibroblasts Produce Interleukin-33 in Response to Stimulation by Retinoblastoma-Binding Protein 9 via Production of Prostaglandin E2

Scientists found that stimulation by RBBP9 induced primary fibroblasts to produce prostaglandin E2 that, in turn, induced fibroblasts to produce IL-33. [Int Immunol] Abstract

Sphaerococcus coronopifolius Bromoterpenes as Potential Cancer Stem Cell-Targeting Agents

Co-cultures of non-malignant human bronchial fibroblasts and malignant human bronchial epithelial cells were implemented and the compounds ability to selectively kill cancer stem cells was evaluated by sphere forming assay. [Biomed Pharmacother] Full Article | Graphical Abstract

LUNG CANCER

Ubiquitin Ligase CHIP Regulates OTUD3 Stability and Suppresses Tumor Metastasis in Lung Cancer

Knockdown of carboxyl terminus of Hsc70-interacting protein (CHIP) stabilized ovarian tumor domain-containing protein 3 (OTUD3) which led to elevated GRP78 levels in lung cancer cells. [Cell Death Differ] Abstract

CAMK2A Supported Tumor Initiating Cells of Lung Adenocarcinoma by Upregulating SOX2 through EZH2 Phosphorylation

Calcium/Calmodulin dependent protein kinase II alpha (CAMK2A) supported tumor initiating cells of lung adenocarcinoma by upregulating SOX2 through EZH2 phosphorylation. [Cell Death Dis] Full Article

The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer

Scientists demonstrated that CHIP-knockdown lung cancer cells were more prone to metastasize to mice lung when injected intravenously or subcutaneously. [Cancers] Full Article

PNO1, which Is Negatively Regulated by miR-340-5p, Promotes Lung Adenocarcinoma Progression through Notch Signaling Pathway

In vitro and in vivo assays suggested that downregulation of PNO1 expression suppressed lung adenocarcinoma cell proliferation and invasion. [Oncogenesis] Full Article

Dual TTK/CLK2 Inhibitor, CC-671, Selectively Antagonizes ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells

The authors demonstrated that CC-671 was an effective ABCG2 reversal agent that enhanced the efficacy of chemotherapeutic drugs in ABCG2-overexpressing lung cancer cells. [Cancer Sci] Abstract

Novel eIF4E/eIF4G Protein-Protein Interaction Inhibitors DDH-1 Exhibits Anti-Cancer Activity In Vivo and In Vitro

Investigators showed that DDH-1 may prompt reactive oxygen species (ROS) generation, decrease the mitochondrial membrane potential (MMP), and stimulate DNA double-strand breaks in A549 cells. [Int J Biol Macromol] Abstract

HAGLROS Is Overexpressed and Promotes Non-Small Cell Lung Cancer Migration and Invasion

Researchers found knockdown of HAGLROS in non-small cell lung cancer cells remarkably suppressed tumor proliferation, migration and invasion. [Jpn J Clin Oncol] Abstract

Subscribe to one of our other 19 science newsletters such as Cancer Stem Cell News & Human Immunology News.

A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin-Proteasome System in Pulmonary Fibrosis

The authors describe how matrix metalloproteinases and ubiquitin-proteosome system alter extracellular matrix composition in idiopathic pulmonary fibrosis lungs and mouse models of pulmonary fibrosis, thereby influencing the alveolar epithelial and mesenchymal cell behavior. [Int J Mol Sci] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

IMFINZI^® (Durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s IMFINZI in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival benefit for adults with extensive-stage small cell lung cancer treated in the 1st-line setting. [AstraZeneca (BusinessWire, Inc.)] Press Release

Gilead Sciences and Arcus Biosciences Establish Ten Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that the companies have entered into a ten year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s pipeline. [Gilead Sciences, Inc.] Press Release

US FDA Approves Takeda’s ALUNBRIG^® (Brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

Takeda Pharmaceutical Company Limited announced that the FDA approved ALUNBRIG for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test. [Takeda Pharmaceutical Company Limited (BusinessWire, Inc.)] Press Release

Europe Bets R&D Spending Will Bring Jobs to Battered Economy

The European Union wants a massive dose of research spending to lift it out of what could be the worst recession in its history. Last week, as part of a €1.85 trillion budget and pandemic recovery proposal, the European Commission, the EU executive arm, unveiled plans to pump €94.4 billion into research over seven years, nearly €11 billion more than originally planned for the program, called Horizon Europe. [ScienceInsider] Editorial

The Pandemic Is Challenging China’s Breakneck Race to the Top of Science

When COVID-19 hit, China was close to surpassing the United States as the leading science funder, two years after it took top place as the biggest producer of scientific articles. And the country has boosted science around the world by supplying other regions with graduate students and postdoctoral scholars, who now number in the hundreds of thousands a year. [Nature News] Editorial

Will the Pandemic Permanently Alter Scientific Publishing?

The COVID-19 crisis has underlined just how fast and open science publishing can be – when scientists want it that way. Researchers working on the pandemic are sharing preliminary results on preprint servers and institutional websites at unprecedented rates, embracing the kind of early, public sharing that physicists and mathematicians have practised for decades. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Science Manager – Lung Diseases (Helmholtz Zentrum München)

NEW Research Group Leader – Cardiopulmonary Institute (Max Planck Institute for Heart and Lung Research)

Postdoctoral Research Fellow – Viral and Bacterial Lung Infections (Johns Hopkins University School of Medicine)

Postdoctoral Associate – Lung Cancer Research (Yale University)

Associate Professor – Cell Biology (Dana-Farber Cancer Institute)

Principal Scientist – Respiratory Inflammation Research (Amgen Inc.)

Branch Chief – Integrative Tumor Epidemiology (NIH National Cancer Institute)

Research Associate – Cystic Fibrosis (Michigan State University)

Postdoctoral Fellowship – Lung Epithelium (Boston University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.